137. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J,
Amukoye E, Bah B, Kassa F (2014) A four-month gatifloxacin-containing regimen for
treating tuberculosis. N Engl J Med 371:1588–1598
138. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, Wu M, Zen L, Sun H, Liu Y (2014)
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
Eur Respir J 25–29
139. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, McColm AA,
Duncan K, Lonsdale JT, Rubin H (2005) Inhibitors of type II NADH: menaquinone
oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci 102:4548–4553
140. Crowle AJ, Douvas GS, May MH (1992) Chlorpromazine: a drug potentially useful for
treating mycobacterial infections. Chemotherapy 38:410–419
141. Hollister LE, Eikenberry DT, Raffel S (1960) Chlorpromazine in nonpsychotic patients with
pulmonary tuberculosis. Am Rev Respir Dis 81:562–566
142. Anquetin G, Greiner J, Mahmoudi N, Santillana-Hayat M, Gozalbes R, Farhati K,
Derouin F, Aubry A, Cambau E, Vierling P (2006) Design, synthesis and activity against
Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new
6-fluoroquinolones. Eur J Med Chem 41:1478–1493
143. Mehra R, Rani C, Mahajan P, Vishwakarma RA, Khan IA, Nargotra A (2016)
Computationally guided identification of novel Mycobacterium tuberculosis GlmU inhibitory
leads, their optimization, and in vitro validation. ACS combinatorial science 18:100–116
144. Janardhan S, John L, Prasanthi M, Poroikov V, Narahari Sastry G (2017) A QSAR and
molecular modelling study towards new lead finding: Polypharmacological approach to
Mycobacterium tuberculosis. SAR QSAR Environ Res 28:815–832
145. Choudhury C, Priyakumar UD, Sastry GN (2015) Dynamics based pharmacophore models
for screening potential inhibitors of mycobacterial cyclopropane synthase. J Chem Inf Model
55:848–860
146. Nandi S, Ahmed S, Saxena A (2018) Combinatorial design and virtual screening of potent
anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and
pharmacophore modelling. SAR QSAR Environ Res 29:151–170
147. Singh S, Mandal PK, Singh N, Misra AK, Singh S, Chaturvedi V, Sinha S, Saxena AK
(2010) Substituted hydrazinecarbothioamide as potent antitubercular agents: synthesis and
quantitative structure–activity relationship (QSAR). Bioorg Med Chem Lett 20:2597–2600
148. Karan S, Kashyap VK, Shafi S, Saxena AK (2017) Structural and inhibition analysis of
novel sulfur-rich 2-mercaptobenzothiazole and 1, 2, 3-triazole ligands against
Mycobacterium tuberculosis DprE1 enzyme. J Mol Model 23:241
149. Zhang G, Guo S, Cui H, Qi J (2018) Virtual screening of small molecular inhibitors against
DprE1. Molecules 23:524
150. Kandasamy S, Hassan S, Gopalaswamy R, Narayanan S (2014) Homology modelling,
docking, pharmacophore and site directed mutagenesis analysis to identify the critical amino
acid residue of PknI from Mycobacterium tuberculosis. J Mol Graph Model 52:11–19
151. Appunni S, Rajisha P, Rubens M, Chandana S, Singh HN, Swarup V (2017) Targeting
PknB, an eukaryotic-like serine/threonine protein kinase of Mycobacterium tuberculosis
with phytomolecules. Comput Biol Chem 67:200–204
152. Dkhar HK, Gopalsamy A, Loharch S, Kaur A, Bhutani I, Saminathan K, Bhagyaraj E,
Chandra V, Swaminathan K, Agrawal P (2014) Discovery of Mycobacterium tuberculosis-1,
4-glucan branching enzyme (GlgB) inhibitors by structure-and ligand-based virtual
screening. J Biol Chem 2015:76–89
153. Muddassar M, Jang JW, Gon HS, Cho YS, Kim EE, Keum KC, Oh T, Cho S-N, Pae AN
(2010) Identification of novel antitubercular compounds through hybrid virtual screening
approach. Bioorg Med Chem 18:6914–6921
154. Naidu KM, Srinivasarao S, Agnieszka N, Ewa A-K, Kumar MMK, Sekhar KVGC (2016)
Seeking potent anti-tubercular agents: design, synthesis, anti-tubercular activity and docking
study of various ((triazoles/indole)-piperazin-1-yl/1, 4-diazepan-1-yl) benzo [d] isoxazole
derivatives. Bioorg Med Chem Lett 26:2245–2250
Impact of Target-Based Drug Design in Anti-bacterial …
345
Amukoye E, Bah B, Kassa F (2014) A four-month gatifloxacin-containing regimen for
treating tuberculosis. N Engl J Med 371:1588–1598
138. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, Wu M, Zen L, Sun H, Liu Y (2014)
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
Eur Respir J 25–29
139. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, McColm AA,
Duncan K, Lonsdale JT, Rubin H (2005) Inhibitors of type II NADH: menaquinone
oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci 102:4548–4553
140. Crowle AJ, Douvas GS, May MH (1992) Chlorpromazine: a drug potentially useful for
treating mycobacterial infections. Chemotherapy 38:410–419
141. Hollister LE, Eikenberry DT, Raffel S (1960) Chlorpromazine in nonpsychotic patients with
pulmonary tuberculosis. Am Rev Respir Dis 81:562–566
142. Anquetin G, Greiner J, Mahmoudi N, Santillana-Hayat M, Gozalbes R, Farhati K,
Derouin F, Aubry A, Cambau E, Vierling P (2006) Design, synthesis and activity against
Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new
6-fluoroquinolones. Eur J Med Chem 41:1478–1493
143. Mehra R, Rani C, Mahajan P, Vishwakarma RA, Khan IA, Nargotra A (2016)
Computationally guided identification of novel Mycobacterium tuberculosis GlmU inhibitory
leads, their optimization, and in vitro validation. ACS combinatorial science 18:100–116
144. Janardhan S, John L, Prasanthi M, Poroikov V, Narahari Sastry G (2017) A QSAR and
molecular modelling study towards new lead finding: Polypharmacological approach to
Mycobacterium tuberculosis. SAR QSAR Environ Res 28:815–832
145. Choudhury C, Priyakumar UD, Sastry GN (2015) Dynamics based pharmacophore models
for screening potential inhibitors of mycobacterial cyclopropane synthase. J Chem Inf Model
55:848–860
146. Nandi S, Ahmed S, Saxena A (2018) Combinatorial design and virtual screening of potent
anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and
pharmacophore modelling. SAR QSAR Environ Res 29:151–170
147. Singh S, Mandal PK, Singh N, Misra AK, Singh S, Chaturvedi V, Sinha S, Saxena AK
(2010) Substituted hydrazinecarbothioamide as potent antitubercular agents: synthesis and
quantitative structure–activity relationship (QSAR). Bioorg Med Chem Lett 20:2597–2600
148. Karan S, Kashyap VK, Shafi S, Saxena AK (2017) Structural and inhibition analysis of
novel sulfur-rich 2-mercaptobenzothiazole and 1, 2, 3-triazole ligands against
Mycobacterium tuberculosis DprE1 enzyme. J Mol Model 23:241
149. Zhang G, Guo S, Cui H, Qi J (2018) Virtual screening of small molecular inhibitors against
DprE1. Molecules 23:524
150. Kandasamy S, Hassan S, Gopalaswamy R, Narayanan S (2014) Homology modelling,
docking, pharmacophore and site directed mutagenesis analysis to identify the critical amino
acid residue of PknI from Mycobacterium tuberculosis. J Mol Graph Model 52:11–19
151. Appunni S, Rajisha P, Rubens M, Chandana S, Singh HN, Swarup V (2017) Targeting
PknB, an eukaryotic-like serine/threonine protein kinase of Mycobacterium tuberculosis
with phytomolecules. Comput Biol Chem 67:200–204
152. Dkhar HK, Gopalsamy A, Loharch S, Kaur A, Bhutani I, Saminathan K, Bhagyaraj E,
Chandra V, Swaminathan K, Agrawal P (2014) Discovery of Mycobacterium tuberculosis-1,
4-glucan branching enzyme (GlgB) inhibitors by structure-and ligand-based virtual
screening. J Biol Chem 2015:76–89
153. Muddassar M, Jang JW, Gon HS, Cho YS, Kim EE, Keum KC, Oh T, Cho S-N, Pae AN
(2010) Identification of novel antitubercular compounds through hybrid virtual screening
approach. Bioorg Med Chem 18:6914–6921
154. Naidu KM, Srinivasarao S, Agnieszka N, Ewa A-K, Kumar MMK, Sekhar KVGC (2016)
Seeking potent anti-tubercular agents: design, synthesis, anti-tubercular activity and docking
study of various ((triazoles/indole)-piperazin-1-yl/1, 4-diazepan-1-yl) benzo [d] isoxazole
derivatives. Bioorg Med Chem Lett 26:2245–2250
Impact of Target-Based Drug Design in Anti-bacterial …
345